Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.

Kishi T, Iwata N.

J Psychiatr Res. 2013 Sep;47(9):1143-9. doi: 10.1016/j.jpsychires.2013.04.013. Epub 2013 May 18.

PMID:
23692933
2.

Sertindole for schizophrenia.

Lewis R, Bagnall AM, Leitner M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715. Review.

PMID:
16034864
3.

N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.

Elahi B, Phielipp N, Chen R.

Can J Neurol Sci. 2012 Jul;39(4):465-72.

PMID:
22728853
4.

Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials.

Kishi T, Mukai T, Matsuda Y, Moriwaki M, Iwata N.

J Psychiatr Res. 2013 Nov;47(11):1557-63. doi: 10.1016/j.jpsychires.2013.07.003. Epub 2013 Jul 27.

PMID:
23899496
5.

Memantine for dementia.

Areosa SA, Sherriff F.

Cochrane Database Syst Rev. 2003;(1):CD003154. Review. Update in: Cochrane Database Syst Rev. 2003;(3):CD003154.

PMID:
12535459
6.

Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.

Kishi T, Mukai T, Matsuda Y, Iwata N.

Neuromolecular Med. 2014 Mar;16(1):61-9. doi: 10.1007/s12017-013-8251-0. Epub 2013 Jul 30. Review.

PMID:
23896722
7.
8.

Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.

Zheng W, Li XH, Yang XH, Cai DB, Ungvari GS, Ng CH, Wang SB, Wang YY, Ning YP, Xiang YT.

Psychol Med. 2018 Jan;48(1):72-81. doi: 10.1017/S0033291717001271. Epub 2017 May 22.

PMID:
28528597
9.

Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.

Kishi T, Matsuda Y, Nakamura H, Iwata N.

J Psychiatr Res. 2013 Feb;47(2):149-54. doi: 10.1016/j.jpsychires.2012.10.011. Epub 2012 Nov 3. Review. Erratum in: J Psychiatr Res. 2013 Oct;47(10):1545.

PMID:
23131856
10.

Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials.

Kishi T, Sevy S, Chekuri R, Correll CU.

J Clin Psychiatry. 2013 Jul;74(7):e642-54. doi: 10.4088/JCP.12r08178.

PMID:
23945459
11.

Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia.

Kishi T, Iwata N.

Int J Neuropsychopharmacol. 2014 Feb;17(2):343-54. doi: 10.1017/S1461145713000667. Epub 2013 Jul 3. Review.

PMID:
23823741
12.

Amisulpride for schizophrenia.

Mota NE, Lima MS, Soares BG.

Cochrane Database Syst Rev. 2002;(2):CD001357. Review.

PMID:
12076408
13.

Early intervention for psychosis.

Marshall M, Rathbone J.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004718. Review. Update in: Cochrane Database Syst Rev. 2011;(6):CD004718.

PMID:
17054213
14.

Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Kishi T, Iwata N.

CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. Review.

PMID:
23812802
15.

Haloperidol versus placebo for schizophrenia.

Joy CB, Adams CE, Lawrie SM.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003082. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD003082.

PMID:
17054159
16.

Quetiapine for schizophrenia.

Srisurapanont M, Maneeton B, Maneeton N.

Cochrane Database Syst Rev. 2004;(2):CD000967. Review.

PMID:
15106155
17.

Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials.

Matsuda Y, Kishi T, Iwata N.

J Psychiatr Res. 2013 Dec;47(12):2018-20. doi: 10.1016/j.jpsychires.2013.09.002. Epub 2013 Sep 15. No abstract available.

PMID:
24079776
18.

Haloperidol versus placebo for schizophrenia.

Joy CB, Adams CE, Lawrie SM.

Cochrane Database Syst Rev. 2001;(2):CD003082. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD003082.

PMID:
11406070
19.

Chlorpromazine versus placebo for schizophrenia.

Thornley B, Rathbone J, Adams CE, Awad G.

Cochrane Database Syst Rev. 2003;(2):CD000284. Review. Update in: Cochrane Database Syst Rev. 2007;(2):CD000284.

PMID:
12804394
20.

Glutamatergic drugs for schizophrenia.

Tuominen HJ, Tiihonen J, Wahlbeck K.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003730. Review.

PMID:
16625590

Supplemental Content

Support Center